Kinoxis Therapeutics
Latest round
- Series B
Last raised
- Apr 2024
Total raised
- $17M
Investors
- 18
About Kinoxis Therapeutics
Based in Victoria, Australia, Kinoxis Therapeutics Pty Ltd was founded in 2017 by Hugh Alsop, Michael Bowen and Michael Kassiou as a University of Sydney spinout developing first-in-class small-molecule therapeutics for central nervous system disorders. Kinoxis Therapeutics is focused on developing small-molecule therapeutics that modulate brain pathways involved in social behaviour. The company's lead product, KNX100, is a novel compound under development for treating substance use disorders and managing symptoms such as agitation and aggression associated with neurodegenerative and neurodevelopmental disorders. KNX100 has completed Phase I clinical trials, demonstrating initial safety and tolerability in humans. In addition to KNX100, Kinoxis is advancing a second program centred on compounds that target the oxytocin receptor. This program explores selective partial agonism and positive allosteric modulation of the oxytocin receptor to enhance social functioning. The company earns revenue through its licensing agreement with Boehringer Ingelheim, which provides an upfront payment, research support payments, eligibility for research, preclinical, clinical, regulatory and commercial milestone payments, and royalties on future product sales.
Who invested in Kinoxis Therapeutics
18 investors across 3 rounds
See all investors in Kinoxis Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Kinoxis Therapeutics
Who invested in Kinoxis Therapeutics?
Kinoxis Therapeutics has 18 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Kinoxis Therapeutics raised?
Kinoxis Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Kinoxis Therapeutics last raise money?
Kinoxis Therapeutics's most recent round on record is a Series B, in Apr 2024.
What does Kinoxis Therapeutics do?
Based in Victoria, Australia, Kinoxis Therapeutics Pty Ltd was founded in 2017 by Hugh Alsop, Michael Bowen and Michael Kassiou as a University of Sydney spinout developing first-in-class small-molecule therapeutics for central nervous system disorders.
Where is Kinoxis Therapeutics headquartered?
Kinoxis Therapeutics is headquartered in Australia.
Which VCs invest in companies like Kinoxis Therapeutics?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Movac back pharmaceuticals companies at Kinoxis Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Kinoxis Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.